Skip to main content
. 2021 Mar 14;128(6):747–757. doi: 10.1111/bcpt.13573

FIGURE 2.

FIGURE 2

The combination of BFOV and metformin ameliorates hepatic steatosis in HFC57 mice. (A, B) Serum ALT and AST determined after 6‐weeks of treatment. (C, D) Hepatic TG and CHO content. (E) Typical liver sections stained with H&E prepared at the end of treatment and captured under a light microscope (Olympus CX41RF, Olympus, Tokyo, Japan. ×100). Scale bar, 200μm. Nor, saline‐treated C57BL/6J mice. Con, saline‐treated HFC57 mice. BFOV, 20 mg/kg BW BFOV‐treated HFC57 mice. Met, 100 mg/kg BW metformin‐treated HFC57 mice. BFOV + Met, 20 mg/kg BW BFOV and 100 mg/kg BW metformin‐treated HFC57 mice. n = 5/group. Values are means ± SEM. One‐way ANOVA: * P <.05, *** P <.001 vs. Con. # P <.05, ## P <.01, ### P <.001 vs. BFOV + Met